VJOncology is committed to improving our service to you

ASCO 2020 | KEYNOTE-426 – Pembrolizumab plus axitinib versus sunitinib for mRCC

VJOncology is committed to improving our service to you

Thomas Powles

Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK, outlines KEYNOTE-426 (NCT02853331), a study that evaluated the efficacy and safety of pembrolizumab in combination with axitinib versus sunitinib monotherapy as a first-line treatment for participants with advanced/metastatic renal cell carcinoma (mRCC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter